Adam Brufsky, MD, PhD - Getting Real With Patients During Clinical Decision-Making: The Value of Sharing Real-World Evidence About CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer

Please visit answersincme.com/VVM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the relevance of real-world evidence on the frontline use of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer. Upon completion of this activity, participants should be better able to: Recognize ways that good quality real-world evidence (RWE) can complement findings from clinical trials in patients with HR+/HER2- metastatic breast cancer (mBC); Outline the clinical relevance of incorporating RWE on the frontline use of CDK4/6 inhibitors into shared decision-making with patients who have HR+/HER2- mBC; and Describe patient-centered strategies to integrate RWE into clinical decision-making discussions with patients who have HR+/HER2- mBC.

There are no comments yet.

Please log in to write the first comment.